#1 Clinical Trials Search in Europe

Marginal zone lymphoma – Trials in Disease

Go back

Ongoing Clinical Trials for Marginal Zone Lymphoma

Marginal zone lymphoma is a slow-growing type of blood cancer affecting B-cells in the immune system. Currently, 13 clinical trials are underway across Europe testing various treatment approaches for patients whose disease has returned or not responded to previous treatments. These studies are evaluating new medications, combination therapies, and innovative cell-based treatments to improve outcomes for patients with this condition.

Clinical trial locations

Study on Golcadomide and Valemetostat Tosylate for Patients with Relapsed or Refractory Non-Hodgkin Lymphomas

This study is testing a new medication called golcadomide both alone and in combination with other therapies for patients whose lymphoma has come back or not responded to previous treatment. Participants will receive golcadomide as oral capsules, which may be given alongside rituximab, obinutuzumab, tafasitamab, or valemetostat tosylate.

To qualify for this trial, patients must be at least 18 years old with confirmed marginal zone lymphoma that has relapsed or become resistant to treatment. Participants need to have adequate blood counts, with specific requirements for neutrophils, hemoglobin, and platelets, and acceptable kidney and liver function. The trial is open to patients with good performance status, able to carry out daily activities with minimal assistance.

The study excludes patients with other types of cancer not specified in the trial, those with serious health conditions that could interfere with treatment, pregnant or breastfeeding women, and those with recent heart attacks or severe heart problems. Patients with active infections requiring treatment or those currently participating in other trials are also excluded.

The main focus of this research is to determine the safety and best dose of golcadomide, and to gather initial information about its effectiveness. The medication works by blocking certain proteins in cancer cells, potentially slowing or stopping their growth.

Study on Lisocabtagene Maraleucel for Adults with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma

This trial evaluates lisocabtagene maraleucel, a form of gene therapy using the patient’s own modified immune cells to fight cancer. The treatment involves collecting T cells from the patient through leukapheresis, modifying them in a laboratory to better recognize cancer cells, and then returning them to the patient through an intravenous infusion.

Eligible participants must be at least 18 years old with confirmed follicular or marginal zone lymphoma that has worsened after at least two previous treatments combining chemotherapy and immune therapy. Patients need good vascular access for the cell collection procedure and must have measurable disease visible on scans. They should have adequate organ function and be able to carry out most daily activities.

The study excludes patients with lymphoma in the central nervous system, those who are pregnant or breastfeeding, and individuals unable to stop certain therapies before cell collection. Before receiving the treatment, patients undergo chemotherapy to prepare their body for the infusion.

The trial will monitor how well the cancer responds to this approach, how long positive effects last, and what side effects may occur. This innovative treatment aims to harness the immune system’s power to target and destroy lymphoma cells more effectively.

Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

This trial provides continued access to ibrutinib for patients who previously participated in ibrutinib studies and continue to benefit from the treatment, particularly in regions where the medication is not commercially available. Ibrutinib is taken as a capsule by mouth.

To participate, patients must have been in an eligible ibrutinib clinical trial, continue to benefit from or wish to restart ibrutinib treatment, and have completed all assessments in their previous study. Commercial ibrutinib must not be available or accessible in their region. Both men and women who can have children must use effective birth control during treatment and for 90 days afterward.

The study excludes patients with certain types of lymphoma or leukemia who don’t meet specific criteria, those outside the age requirements, individuals not eligible for long-term access, and vulnerable populations requiring special protection.

Ibrutinib works by blocking a protein that helps cancer cells grow and survive. Throughout the trial, patients are monitored for serious side effects, and regular safety assessments are conducted to ensure the treatment remains beneficial.

Study Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

This study compares two different treatment combinations for patients with lymphoma that has returned or not responded to previous therapy. Participants are randomly assigned to receive either zanubrutinib with obinutuzumab or lenalidomide with rituximab. Zanubrutinib and lenalidomide are taken as oral capsules, while obinutuzumab and rituximab are given through intravenous infusion.

Patients must be at least 18 years old with confirmed follicular or marginal zone lymphoma that requires treatment and has not responded adequately to at least one previous therapy including an anti-CD20 antibody. They need at least one measurable tumor and adequate organ function. Women of childbearing potential must use highly effective contraception and have negative pregnancy tests.

The study excludes patients with different types of lymphoma not specified in the trial and those outside the age range. Throughout the study, regular monitoring includes blood tests, imaging scans, and quality of life questionnaires to assess treatment effectiveness and any side effects.

The trial aims to determine which combination is more effective at controlling the cancer and how each affects overall health and quality of life. This information could help improve future treatment strategies.

Study of Acalabrutinib and Tafasitamab for Patients with Previously Treated Marginal Zone Lymphoma

This trial tests the combination of acalabrutinib and tafasitamab for patients with marginal zone lymphoma that has returned or not responded to treatment. Acalabrutinib is taken as oral capsules, while tafasitamab is given through intravenous infusion.

Eligible participants must be at least 18 years old with confirmed marginal zone lymphoma that is relapsed or refractory and requires treatment. This includes specific symptoms such as disease progression, large tumors, or worsening blood counts. Patients need adequate kidney and liver function, normal blood clotting ability, and be able to swallow capsules. Women of childbearing potential must use effective birth control and not be pregnant or breastfeeding.

The study excludes patients who haven’t received prior systemic therapy, those not within the specified age range, and individuals not meeting specific eligibility criteria. Acalabrutinib works by blocking proteins in cancer cells to slow their growth, while tafasitamab helps the immune system recognize and destroy cancer cells.

The trial will monitor treatment response through regular evaluations and assess safety throughout the study period, which may last up to 24 months.

Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

This trial evaluates axicabtagene ciloleucel, a CAR T-cell therapy that uses modified immune cells to target cancer. The treatment involves collecting T cells from patients, modifying them in a laboratory to better recognize lymphoma cells, and returning them through intravenous infusion.

Patients must be at least 18 years old with follicular or marginal zone lymphoma that has worsened after at least two treatments combining chemotherapy and immunotherapy. They need measurable disease on scans, no lymphoma in the central nervous system, and adequate kidney, liver, lung, and heart function. Both men and women must agree to use birth control for 12 months after treatment.

The study excludes patients with other cancer types, pregnant or breastfeeding women, and those unable to stop certain therapies before cell collection. Before the CAR T-cell infusion, patients receive chemotherapy with fludarabine and cyclophosphamide to prepare their body.

The trial monitors how well the treatment works by assessing cancer response at specific intervals and tracking long-term outcomes for up to 15 years. This approach aims to use the body’s immune system more effectively against cancer cells.

Study of capivasertib tablets in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

This study tests capivasertib, an oral medication that blocks specific proteins cancer cells need to grow and survive. The medication comes in 160 mg and 200 mg tablets and is being studied in patients with follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma that has returned or not responded to previous treatments.

Eligible participants must be at least 18 years old with confirmed B-cell lymphoma requiring treatment. They need measurable disease on CT or MRI scans, with at least one lymph node larger than 1.5 cm or one lesion outside lymph nodes larger than 1 cm. Patients must have good performance status, adequate organ function, and a life expectancy of more than 6 months. Female patients must have a negative pregnancy test.

The study excludes patients who previously received CAR-T cell therapy, those with active brain metastases, recent or unstable heart conditions, active infections, pregnancy or breastfeeding, recent major surgery, or participation in other trials.

Throughout the study, regular monitoring includes imaging tests, blood tests to measure drug levels, quality of life questionnaires, vital sign checks, and heart rhythm monitoring to assess treatment effectiveness and safety.

Study of Ibrutinib and Rituximab for Patients with Untreated Marginal Zone Lymphoma

This trial evaluates the combination of ibrutinib and rituximab as a first treatment for patients with marginal zone lymphoma. Ibrutinib is taken daily as oral capsules, while rituximab is given as an injection under the skin or through intravenous infusion at specific intervals.

Patients must have CD20-positive marginal zone lymphoma that has not been treated before and causes symptoms requiring systemic therapy. This includes patients unable to receive local treatments like surgery or radiotherapy. Eligibility varies by lymphoma subtype, with specific criteria for extranodal, splenic, and nodal types. Patients need adequate kidney function, measurable disease, and be at least 18 years old with a life expectancy of at least one year.

The study excludes patients who already received treatment, those without symptoms, patients whose lymphoma is not CD20-positive, and those who don’t need systemic treatment. Both men and women who can have children must use effective birth control during treatment and for a period afterward.

The trial will assess how well the combination works by measuring complete response rates, progression-free survival, and overall survival, while monitoring for side effects throughout the study period.

Study of Obinutuzumab as First-Line Treatment for Adult Patients with Marginal Zone Lymphoma Who Are Not Eligible for Local Therapy

This study evaluates obinutuzumab as a single-agent first treatment for patients with marginal zone lymphoma who cannot receive local treatments or for whom local treatments have not worked. The medication is given through intravenous infusion at a dose of 1,000 mg.

Eligible participants must be at least 18 years old with CD20-positive marginal zone lymphoma requiring treatment. They need at least one measurable tumor of 1.5 cm or larger visible on CT scan or MRI, a life expectancy of more than 3 months, and normal kidney function. Women who can become pregnant must have a negative pregnancy test and agree to use effective birth control during treatment and for 18 months afterward.

The study excludes patients younger than 18, those who previously received systemic treatment or obinutuzumab, individuals with active infections including hepatitis B, hepatitis C, or HIV, those with serious heart conditions or severe organ dysfunction, pregnant or breastfeeding women, and patients with other active cancers requiring treatment.

The treatment period may last up to 30 months, with regular monitoring including imaging tests, blood tests, and quality of life assessments to evaluate response to treatment and any side effects.

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

This trial compares two treatment approaches for patients with lymphoma that has returned or not responded to treatment. Participants are randomly assigned to receive either a combination of tafasitamab, lenalidomide, and rituximab, or lenalidomide and rituximab with a placebo. Tafasitamab and rituximab are given through intravenous infusion, while lenalidomide is taken as oral capsules.

Participants must be at least 18 years old with confirmed follicular or marginal zone lymphoma that has relapsed or become refractory after at least one previous treatment including anti-CD20 immunotherapy. The disease must have returned after an initial response lasting at least 6 months, failed to respond well to the most recent treatment, or worsened after showing stable disease.

The study excludes patients with different cancer types not specified in the trial, those who haven’t experienced disease return or worsening, individuals outside the age range, and vulnerable populations. Throughout the trial, participants undergo regular check-ups, blood tests, and other assessments to monitor treatment response and safety.

The medications work together by helping the immune system recognize and destroy cancer cells. The trial aims to determine whether adding tafasitamab to the standard combination improves treatment outcomes for patients with these types of lymphoma.

Summary

The clinical trial landscape for marginal zone lymphoma shows significant geographic concentration, with most studies conducted across Western and Central European countries. France appears in 9 out of 13 trials, followed by Italy, Spain, and Germany with strong representation. This distribution reflects the established research infrastructure and patient populations in these countries.

The trials focus on several therapeutic approaches. Traditional targeted therapies like ibrutinib, zanubrutinib, and acalabrutinib are being tested, often in combination with monoclonal antibodies such as rituximab, obinutuzumab, or tafasitamab. A notable development is the evaluation of CAR T-cell therapies, including lisocabtagene maraleucel and axicabtagene ciloleucel, which represent innovative cell-based treatments modifying patients’ own immune cells to fight cancer.

Most studies target patients with relapsed or refractory disease, though some evaluate first-line treatments for newly diagnosed patients. Several trials compare different drug combinations to identify the most effective approaches. The research includes both established medications like ibrutinib and rituximab, as well as newer agents such as golcadomide, capivasertib, and odronextamab.

Patient eligibility typically requires confirmed marginal zone lymphoma diagnosis, adequate organ function, and acceptable performance status. Many trials specifically include patients whose disease has not responded to at least two previous treatments. The studies employ various outcome measures including response rates, progression-free survival, and safety assessments to evaluate treatment effectiveness.

Ongoing Clinical Trials on Marginal zone lymphoma

  • A Study of Zanubrutinib for Patients with Anti-MAG Antibody Neuropathy Associated with Blood Disorders or Abnormal Protein in the Blood

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study Comparing Odronextamab and Lenalidomide with Rituximab and Lenalidomide for Patients with Relapsed/Refractory Follicular and Marginal Zone Lymphoma

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +2

  • Study of capivasertib tablets in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Hungary Italy Poland Spain +1

  • Study of Obinutuzumab as First-Line Treatment for Adult Patients with Marginal Zone Lymphoma Who Are Not Eligible for Local Therapy

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on MB-CART19.1 for Patients with Relapsed or Refractory CD19 Positive B Cell Malignancies

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effects and Safety of Odronextamab for Adults with Previously Treated B-cell Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Poland Spain

  • Study on Lisocabtagene Maraleucel for Adults with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Austria France Germany Italy Spain Sweden

  • Study of Ibrutinib and Rituximab for Patients with Untreated Marginal Zone Lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Italy Portugal

  • Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

More information about
Marginal zone lymphoma:

Connected medications: